Study compares efficacy and adherence to triple nucleoside therapy Ziagen + Combivir with protease inhibitor plus Combivir regimens in therapy-nave
A study found that 74% of patients taking Ziagen/Combivir had viral loads below 400 copies/ml at 24 weeks, compared to 57% on the PI-containing regimen. Patients on Ziagen/Combivir also reported fewer difficulties with their triple regimen. The study assessed efficacy, safety, and patient adherence in therapy-naive patients.